Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.

LaKendria K BrownThanigaivelan KanagasabaiGuoliang LiSherly I CeladaJelonia T RumphSamuel E AdunyahLaMonica V StewartZhenbang Chen

Published in: The Prostate (2024)

Combined inhibition of KDM5B and SKP2 was more effective at inhibiting proliferation and migration of CRPC cells, and this regimen would be an ideal therapeutic approach of controlling CRPC malignancy.

Keyphrases

cell cycle arrest
prostate cancer
signaling pathway
induced apoptosis
pi k akt
cell death
endoplasmic reticulum stress
oxidative stress
radical prostatectomy
cell proliferation
dna damage
endothelial cells
cancer therapy
stress induced
drug delivery